Document is current

Article History

Received: 7 June 2023

Accepted: 27 November 2023

First Online: 12 December 2023

Declarations

:

: The contents of EU Directive 2010/63 on the protection of animals used for scientific purposes were upheld at all times, as were Spanish regulations (RD 53/20013). The study was reviewed and approved under title “Treatment of peritoneal sepsis with adipose derived mesenchymal stem cells in a porcine model” by the Ethics Committee of the Community of Madrid for animal experimentation (No-PROEX 235/19) on January 17, 2020. These studies were conducted in accordance with the ethical standards of the Helsinki Declaration (1975). Our centre was authorized for the harvesting of adipose tissue cells by the Community of Madrid in 2014 and renewed on 8 July 2020 (ref. 47/210500.9/20), and the use of mesenchymal stem cells from donors for experimental treatments and research was approved by the CEIC of the Instituto de Investigación sanitaria Fundación Jiménez Díaz on 17 April 2020 (Ref. PIC_FJD_2020/32).

: Not applicable.

: MG-A and DG-O have applied for two patents related with this study, entitled “Identification and isolation of multipotent cells from nonosteochondral mesenchymal tissue” (WO 2006/057649) and “Use of adipose tissue-derived stromal stem cells in treating fistula” (WO 2006/136244). DG-O is a member of the Advisory Board of Tigenix SAU and received fees from Takeda. JMM has received research support not related to this manuscript from Roche, Pfizer, Jazz Pharma, Sandoz-Novartis, Gilead, Celgene, and Takeda. The remaining authors have no other financial or competing interests to declare.